Observational studyRevista medica del Instituto Mexicano del Seguro Social2026
Response to benralizumab in patients with severe eosinophilic asthma.
Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe asthma represents a significant public health challenge, and monoclonal antibodies such as benralizumab represent an effective therapeutic option for achieving disease control. Objective: To evaluate the effectiveness of benralizumab in patients with severe eosinophilic asthma by assessing changes in fractional exhaled nitric oxide (FeNO), peripheral blood eosinophils, symptom control, forced expiratory volume in 1 second (FEV1), and exacerbation rates six months after treatment initiation. Materials and methods: A prospective observational study was conducted in 11 patients with severe uncontrolled eosinophilic asthma. Clinical outcomes (ACT), quality of life (mini-AQLQ), FEV1, exacerbations, and biomarkers of blood eosinophils and FeNO were assessed at baseline and six months. Results: After six months of benralizumab therapy, > 90% of patients showed significant improvement in quality of life (mini-AQLQ, p < 0.05), and 72.7% achieved better asthma control (ACT, p < 0.05). Exacerbations decreased by 66.9% (p < 0.05). Blood eosinophils decreased by 97.5% (p < 0.05), FeNO by 57% (p < 0.05), and FEV1 increased by 27.7% (p < 0.05). Conclusions: Benralizumab demonstrated significant clinical and inflammatory benefits in this cohort, improving biomarkers, lung function, exacerbation rates, and patient-reported outcomes, supporting its effectiveness in real-world management of severe eosinophilic asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.